Disclaimer: Note that the firm is no longer accepting cases for the anti-psychotic medication Abilify or Tylenol autism cases. Thank you.
Select Page

Xarelto Litigation Heads to Trial

The U.S. District Judge Eldon E. Fallon overseeing more than 18,000 Xarelto lawsuits ordered that hundreds of those cases be prepared for two waves as the blood thinner litigation heads to trial. Each wave will have 600 lawsuits. The Plaintiffs Steering Committee, Defendants Counsel and the Court will each select 200 cases for each wave. The court will hear the cases from each wave on April 16th.

 

About Xarelto

Xarelto BleedingXarelto came on the market in 2011. Patients use the anticoagulant to reduce the risk of deep vein thrombosis (DVT), pulmonary embolism (PE), and blood clots. Manufacturers Bayer and Janssen promote the drug has the gold standard for anticoagulants. However, it may be more dangerous than other medications on the market since there is no antidote.

By stopping the blood from clotting, blood-thinners can prevent blood clots in people suffering from conditions such as atrial fibrillation. Due to the risk of unstoppable bleeding, researchers developed an “antidote” to stop this effect in the case of emergency in users of warfarin, the most popular anticoagulant for decades.

 

Xarelto Case Management Order

In a Case Management Order dated February 27th, U.S. District Judge Eldon E Fallon of the Eastern District of Louisiana, indicated that a total of 1,200 Xarelto cases need to be selected for two waves of discovery. Each wave will have 600 lawsuits. The Plaintiffs Steering Committee, Defendants Counsel, and the Court will each select 200 cases for each wave. The court will hear the cases from each wave on April 16th.

The first wave of discovery will include Xarelto lawsuits meeting core requirements for the Plaintiff Fact Sheet on or before January 31, 2018. Another requirement is a patient suffering from intracranial hemorrhage or a plaintiff received hospitalization. Plaintiffs must have met those requirements prior to March 30, 2018, for inclusion in the second wave.

On March 16, both sides will examine centrality data to determine the percentage of cases alleging an Intracranial Hemorrhage as an injury. This is because no more than double this percentage will be eligible for Wave 1 selection by the Plaintiffs Steering Committee. Additionally, this includes hospitalization.

 

Xarelto Lawsuit

MoneyThousands of patients are speaking out against Xarelto. They decided to take a stand and ask for compensation from the manufacturers Bayer and Janssen. They feel these companies are profiting from their pains and their loved ones’ deaths. The drug is dangerous because the administration can be difficult, and it can complicate the healing of wounds. There is a tiny window of time between a safe dose and a dangerous one. Overdose or not enough of the medication is a grim reality.

Xarelto lawsuits are similar to lawsuits over Pradaxa, another newer-generation anticoagulant. Michael Brady Lynch, the founder of The Michael Brady Lynch Firm is leading the country in Pradaxa lawsuits. Michael was a member of the Plaintiff’s Steering Committee in the Pradaxa Multi-District Litigation and was instrumental in securing the $650 million settlement for those injured by Pradaxa’s uncontrollable bleeding. Mr. Lynch continues to be a leader in Pradaxa litigation nationwide. He represents those who continue to suffer uncontrollable bleeding events from Pradaxa.

Attorney Lynch has said, “The U.S. numbers for Pradaxa bleeding events are truly staggering. It is on the verge of a national health disaster.”

 

Speak to an Attorney Today

If you or a loved one has been harmed by Xarelto, you need an attorney with experience helping people who have been harmed by pharmaceutical drugs. The attorneys at the Michael Brady Lynch Firm know what it takes to go up against drug manufacturers to get clients what they need.

×
What Our Clients Are Saying